Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)
Status:
Completed
Trial end date:
2019-11-04
Target enrollment:
Participant gender:
Summary
This study will employ a phase Ib design using the established dose of CAVATAK with
pembrolizumab in subjects with advanced melanoma for whom pembrolizumab would be considered
standard of care. Our hypothesis is that oncolysis of melanoma cells by CAVATAK will be
important in amplifying the T-cell potentiating effects of pembrolizumab.